Status:
UNKNOWN
Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy
Lead Sponsor:
Singapore National Eye Centre
Conditions:
Choroidal Neovascularisation
Polypoidal Choroidal Vasculopathy
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
To assess the use of Avastin for the management of serosanguinous maculopathy
Detailed Description
METHODOLOGY Patients will be recruited from the vitreoretinal clinics at SNEC. After initial assessment, clinically and angiographically, the patient will be counselled with regards to diagnosis, pro...
Eligibility Criteria
Inclusion
- All subfoveal/juxtafoveal CNV and PCV (polypoidal choroidal vasculopathy) who are not eligible for other treatment options (compassionate use)
- CNV and PCV lesions which have failed PDT, conventional argon laser photocoagulation (salvage use)
- CNV and PCV lesions treatable with PDT, but cannot afford or refused
Exclusion
- Patients with uncontrolled hypertension (systolic BP greater than 150mmHg or diastolic BP greater than 90mmHg
- History of thrombolic events such as myocardial infarction or cerebral vascular accident
- Renal abnormalities (as defined by established history of chronic renal disease or renal failure as well as patients requiring dialysis).
- Recent (as defined as the past 28 days) or planned (as defined as the next 3 months) surgery.
- Coagulation abnormalities, including anti-coagulant medication other than aspirin
- Patients with peptic ulcer disease
- Pregnant or lactating females
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2008
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00344617
Start Date
June 1 2006
End Date
May 1 2008
Last Update
September 26 2007
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.